

August 17, 2009

Alert of Change in Quantity Level Limit for Certain Migraine Medications

Dear :

Starting October 1, 2009, the quantity level limit (QLL) allowed for certain medications used to treat migraines for Georgia Medicaid Fee-for-Service (FFS) members will change from 18 tablets to 9 tablets in a 34-day period for any migraine medication known as a triptan. The medications affected by this change in limit include Amerge[®], Axert[®], Frova[®], Imitrex[®], Maxalt[®], Relpax[®], sumatriptan, Treximet[®] and Zomig[®] tablets.

This change in quantity limit was recommended and supported by the Department of Community Health's Drug Utilization Review Board (DURB), made up of physicians, pharmacists and a consumer advocate. The DURB believes that lowering the quantity of triptan products will promote treatment for Medicaid members who continually suffer from frequent migraines and who may be candidates for preventive therapy.

Treating more than two migraines a week can cause other types of headaches. People who have more than two migraines a week should be evaluated by their physician for migraine prevention therapy.

This letter is not intended to replace the care you receive by your physician. Please discuss with your physician if therapy that prevents migraine headaches is right for you. The medical need for use of a triptan product to treat your migraines will not affect your Medicaid coverage.

Sincerely,

Georgia Department of Community Health
Medicaid Fee-For-Service Program